Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the study is: - To determine the proportion of subjects treated with luspatercept plus BSC versus placebo plus BSC who achieved erythroid response, defined as ≥ 33% reduction from baseline in transfusion burden (units RBCs / time) with a reduction of at least 2 units, from Week 13 to Week 24.
Inclusion criteria
- Adults who require regular Red Blood Cell (RBC) transfusions due to Beta-Thalassemia